If complete remission cannot be achieved in patients with HER2-positive breast cancer despite exhausting current treatment options, the risk of recurrence is high. Results from an open-label phase III trial of trastuzumab emtansine raise hope.
If complete remission cannot be achieved in patients with HER2-positive breast cancer despite exhausting current treatment options, the risk of recurrence is high. Results from an open-label phase III trial of trastuzumab emtansine raise hope.
Input your search keywords and press Enter.